Autres langues BioLineRx Ltd.

Actions

BLRX

IL0011015182

Marché Fermé - TEL AVIV STOCK EXCHANGE Autres places de cotation 16:25:00 15/05/2024			Varia. 5j.	Varia. 1 janv.
16,3 ^ILa	+0,62%		-2,40%	-57,33%

17/04	BioLineRx Ltd. annonce la présentation d'un poster sur l'efficacité des centres d'aphérèse et les antagonistes du CXCR4, y compris APHEXDA® (Motixafortide) chez les patients atteints de myélome multiple, lors de la réunion annuelle de l'ASFA 2024.	CI
01/04	Les actions de BioLineRx chutent après une offre directe enregistrée de 6 millions de dollars	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

BioLineRx : Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024	06/05
BioLineRx : Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	17/04
BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	17/04
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	10/04
BioLineRx Ltd. Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	10/04
BioLineRx Announces $6 Million Registered Direct Offering	02/04
BioLineRx Shares Fall After $6 Million Registered Direct Offering	01/04
BioLineRx : Form 20-F/A (Amendment No. 1	28/03
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates	27/03
BioLineRx : Annual Report on Form 20-F FOR 2023	26/03
BioLineRx : Report of Periodic or Interim Report	26/03
BioLineRx : Reports 2023 Financial Results and Recent Corporate and Portfolio Updates	26/03
BioLineRx Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024	20/03
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production	04/03
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (Bl-8040) Suitable for Large Scale Production	04/03
Biolinerx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer	28/02
BioLineRx Ltd. Announces Acceptance of Two Poster Presentations on APHEXDA®? (Motixafortide) for CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT®?	16/02
BioLineRx : FORM F-3-REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933	31/12
BioLineRx : FORM S-8-registration of Ordinary Shares to be issued under the Plan	31/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues BioLineRx Ltd.

Actions

BLRX

IL0011015182

Autres langues

Filtres